Affiliated with a Castle Connolly Top Hospital
Who is Dr. Colevas, Medical Oncologist in Stanford, CA?
Dr. Alexander Colevas, MD is a Medical Oncologist, who primarily practices in Stanford, CA. He is board certified. Dr. Colevas completed his residency at Johns Hopkins School of Medicine. Dr. Colevas is fluent in English, and is currently seeing new patients. Dr. Colevas’s practice accepts Kaiser Permanente, Medicaid, Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Colevas’s office at (650) 498-6000.
What are Areas of Expertise for Dr. Colevas?
Dr. Alexander Colevas, MD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Colevas empowers patients to confidently navigate their health journey, specializing in Head & Neck Cancer, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Colevas is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Colevas go to medical school and complete their residency?
Fellowship: Dana Farber Cancer Institute
Residency: Johns Hopkins School of Medicine
Is Dr. Colevas board certified as a Medical Oncologist?
Yes, Dr. Alexander Colevas, MD is board certified by the American Board of Internal Medicine since 1995
What languages does Dr. Colevas speak?
Dr. Colevas and their clinical team can communicate with patients in the following languages:
English
What conditions does a Medical Oncologist like Dr. Colevas typically treat?
As a Medical Oncologist, Dr. Colevas diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Colevas. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Throat Cancer
- Oral Cancer
- Nasopharyngeal Cancer
- Malignant Neoplasm of Nasopharynx
- Pharyngeal Cancer
- Oropharyngeal Cancer
- Malignant Neoplasm of Oropharynx
- Tonsil Cancer
- Malignant Neoplasm of Tonsil
ICD-10 Codes:
- C119: Malignant neoplasm of nasopharynx, unspecified
- C109: Malignant neoplasm of oropharynx, unspecified
- C099: Malignant neoplasm of tonsil, unspecified
Also known as:
- Thyroid Cancer
- Thyroid Carcinoma
- Malignant Thyroid Nodule
- Thyroid Gland Cancer
ICD-10 Codes:
- C73: Malignant neoplasm of thyroid gland
Also known as:
- Oral Cancer
- Mouth Cancer
- Tongue Cancer
- Oral Cavity Cancer
- Tongue Carcinoma
ICD-10 Codes:
- C01: Malignant neoplasm of base of tongue
Also known as:
- Head and Neck Cancer
- Head Cancer
- Neck Cancer
- Facial Cancer
- Malignant Head and Neck Tumor
ICD-10 Codes:
- C760: Malignant neoplasm of head, face and neck
What procedures does a Medical Oncologist like Dr. Colevas typically perform?
As a Medical Oncologist, Dr. Colevas performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Colevas. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Swallowing Therapy
- Dysphagia Treatment
- Feeding Therapy
- Oral Function Therapy
CPT Codes:
- 92526: Treatment of swallowing dysfunction and/or oral function for feeding
Also known as:
- Flexible Endoscopic Swallowing Evaluation (FEES)
- Swallowing Function Test
- Swallowing Study (Videofluoroscopy)
- Endoscopy
- Dysphagia Tests
- FEES Test
- Swallowing Endoscopy
- Video Swallowing Study
- Dysphagia Endoscopy
- Dysphagia Evaluation
- Oral Swallowing Assessment
- Pharyngeal Swallowing Test
- Swallowing Study
- Videofluoroscopic Swallowing Study (VFSS)
- Modified Barium Swallow (MBS)
CPT Codes:
- 92612: Flexible endoscopic evaluation of swallowing by cine or video recording;
- 92610: Evaluation of oral and pharyngeal swallowing function
- 92611: Motion fluoroscopic evaluation of swallowing function by cine or video recording
Also known as:
- Individual Speech and Language Therapy
- Speech-Language Pathology
- Voice Therapy
- Communication Disorder Treatment
- Auditory Processing Therapy
CPT Codes:
- 92507: Treatment Of Speech, Language, Voice, Communication, And/Or Auditory Processing Disorder; Individual
Also known as:
- Voice Prosthetic Fitting
- Speech Prosthesis Evaluation
- Voice Device Assessment
- Artificial Voice Fitting
CPT Codes:
- 92597: Evaluation for use and/or fitting of voice prosthetic device to supplement oral speech
Also known as:
- Flexible Diagnostic Laryngoscopy
- Voice Box Exam
- Flexible Laryngoscope
- Throat Scope
- Diagnostic Throat Exam
CPT Codes:
- 31575: Laryngoscopy, flexible; diagnostic
Also known as:
- PICC Line Insertion (Adult/Older Child)
- Peripherally Inserted Central Catheter
- PICC Line Placement
- Central Venous Catheter Insertion
CPT Codes:
- 36573: Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; age 5 years or older
Does Dr. Colevas accept my insurance?
Dr. Colevas accepts most major insurance plans. Important: Please call our office at (650) 498-6000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Colevas accept in Stanford, CA?
Dr. Colevas in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Alignment Healthcare
All Other Third Party
Blue Shield of California
Cigna Group
CVS Health (formerly Aetna)
Medicaid
Medicare
OptumRx Administered Payer
State of California
UnitedHealth Group
View All Insurances
Where is Dr. Colevas' office located?
Recognitions
Publications
Head and Neck Cancers, Version 2.2013 Featured Updates to the NCCN Guidelines
, 2013
Stereotactic radiosurgery for retreatment of gross perineural invasion
, 2013
Biased View of the Role of Site-Specific Therapy in Carcinoma of Unknown Primary.
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3
, 2012
Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors
, 2012
A phase I dose-escalation study of aflibercept administered in combition with pemetrexed
, 2012
Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer
, 2012
Phase I trial of the combition of flavopiridol and imatinib mesylate in patients with Bcr-Abl
, 2012
Effect of stimulation of tural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab
Intensity-Modulated Radiotherapy for Tumors of the sal Cavity and Parasal Sinuses
, 2012
Maintence Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced
, 2012
Mucosal Melanoma of the Head and Neck
, 2012
Stimulation of tural killer cells with a CD137
, 2012
Addition of bevacizumab to st
, 2012
The use of epidermal growth factor receptor monoclol antibodies
, 2012
Head and Neck Cancers
, 2011
Controversies in the Locoregiol Magement of Head and Neck Cancer
, 2011
INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX
, 2011
A Phase II First-Line Study of Gemcitabine, Carboplatin
, 2010
HIGHER INCIDENCE OF HEAD AND NECK CANCERS AMONG VIETMESE AMERICAN MEN IN CALIFORNIA
, 2010
MOLECULAR AND CLINICAL RESPONSES IN A PILOT STUDY OF GEFITINIB WITH PACLITAXEL AND RADIATION IN
, 2010
LONG-TERM OUTCOMES AND TOXICITY OF CONCURRENT PACLITAXEL AND RADIOTHERAPY FOR LOCALLY ADVANCED HEAD
, 2009
Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer?
, 2009
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone
, 2008
Head and neck cancers.
, 2008
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
, 2008
Patient-reported outcomes and the evolution of adverse event reporting in oncology
, 2007
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
, 2007
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors
, 2007
Phase I and correlative biology study of cilengitide in patients with recurrent malignt glioma
, 2007
A phase II study of ixabepilone (BMS-247550) in metastatic rel-cell carcinoma
, 2007
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea
, 2007
Adverse event reporting in publications compared with sponsor database for cancer clinical trials
, 2006
Chemotherapy options for patients with met
, 2006
Phase II evaluations of cilengitide in asymptomatic patients with
, 2006
Ixabepilone (epothilone B alogue BMS
, 2005
Phase I trial and pharmacokinetics of escalating doses of paclitaxel
, 2005
Multi-institutiol randomized phase II trial of the epothilone B alog ixabepilone
, 2005
Phase II trial of flavopiridol, a cyclin dependent kise inhibitor
, 2004
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer
, 2003
Development of investigatiol radiation modifiers
, 2003
Phase I/II trial of outpatient docetaxel
, 2002
Hypothyroidism incidence after multimodality treatment for stage III
, 2001
Clinical trials referral resource: Current clinical trials of epothilone B alog (BMS-247550)
, 2001
Multicenter phase I-II trial of docetaxel, cisplatin
, 2001
The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head
, 2000
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous
, 2000
Phase II trial of docetaxel, cisplatin
, 1999
Intramucosal spread of malignt melanoma of the oral cavity
, 1998
Docetaxel in head and neck cancer - A review
, 1998
Induction chemotherapy with docetaxel, cisplatin
, 1998
Long-Term Outcomes of Surgery Followed by Radiation Therapy for Minor Salivary Gland Carcinomas
, 2013
Head and Neck Cancers, Version 2.2013 Featured Updates to the NCCN Guidelines
, 2013
Stereotactic radiosurgery for retreatment of gross perineural invasion
, 2013
Impact of positron emission tomography
, 2013
Biased View of the Role of Site-Specific Therapy in Carcinoma of Unknown Primary.
Population-based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with
, 2013
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3
, 2012
A Phase 2 Trial of Flavopiridol
, 2012
Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors
, 2012
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed
, 2012
Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer
, 2012
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma
, 2012
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl
, 2012
Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab
Intensity-Modulated Radiotherapy for Tumors of the Nasal Cavity and Paranasal Sinuses
, 2012
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with
, 2012
Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced
, 2012
Mucosal Melanoma of the Head and Neck
, 2012
Stimulation of natural killer cells with a CD137
, 2012
Addition of bevacizumab to st
, 2012
The use of epidermal growth factor receptor monoclonal antibodies
, 2012
Head and Neck Cancers
, 2011
Controversies in the Locoregional Management of Head and Neck Cancer
, 2011
INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX
, 2011
A Phase II First-Line Study of Gemcitabine, Carboplatin
, 2010
HIGHER INCIDENCE OF HEAD AND NECK CANCERS AMONG VIETNAMESE AMERICAN MEN IN CALIFORNIA
, 2010
MOLECULAR AND CLINICAL RESPONSES IN A PILOT STUDY OF GEFITINIB WITH PACLITAXEL AND RADIATION IN
, 2010
Excellent early local control with tumor volume adapted dosing of stereotactic body radiation
, 2009
LONG-TERM OUTCOMES AND TOXICITY OF CONCURRENT PACLITAXEL AND RADIOTHERAPY FOR LOCALLY ADVANCED HEAD
, 2009
Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer?
, 2009
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone
, 2008
Head and neck cancers.
, 2008
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
, 2008
Patient-reported outcomes and the evolution of adverse event reporting in oncology
, 2007
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
, 2007
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors
, 2007
Sequential flavopiridol, cytosine arabinoside
, 2007
Inhibition of poly (ADP
, 2007
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma
, 2007
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma
, 2007
Flavopiridol administered using a pharmacologically derived schedule is
, 2007
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea
, 2007
Adverse event reporting in publications compared with sponsor database for cancer clinical trials
, 2006
Chemotherapy options for patients with met
, 2006
Phase II evaluations of cilengitide in asymptomatic patients with
, 2006
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea
, 2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta
, 2005
Ixabepilone (epothilone B analogue BMS
, 2005
Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent
, 2005
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone
, 2005
Current clinical trials of cilengitide
, 2004
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor
, 2004
HER2 expression in salivary gland carcinomas: Dependence on histological subtype
, 2004
Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study
, 2003
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer
, 2003
Development of investigational radiation modifiers
, 2003
Docetaxel, cisplatin
, 2003
Organ preservation-induction chemotherapy.
, 2003
Timed sequential therapy of acute leukemia with flavopiridol
, 2003
A Phase I/II trial of concurrent docetaxel and radiation
, 2002
Phase I/II trial of outpatient docetaxel
, 2002
Hypothyroidism incidence after multimodality treatment for stage III
, 2001
Clinical trials referral resource: Current clinical trials of epothilone B analog (BMS-247550)
, 2001
A Phase II study of combined oral uracil
, 2001
Multicenter phase I-II trial of docetaxel, cisplatin
, 2001
NCCN Practice Guidelines for head and neck cancers
, 2000
The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head
, 2000
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous
, 2000
Phase II trial of docetaxel, cisplatin
, 1999
Re: Sialadenosis: a presenting sign in Bulemia (Head and Neck 20: 758-762, 1998)
, 1999
An initial experience using concurrent paclitaxel and radiation
, 1999
Intramucosal spread of malignant melanoma of the oral cavity
, 1998
Docetaxel in head and neck cancer - A review
, 1998
Induction chemotherapy with docetaxel, cisplatin
, 1998
The Prognostic Value of Thymidylate Synthase
, 1998
Future directions in the treatment of squamous cell carcinoma of the head and neck
, 1997
What is Dr. Colevas's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Colevas's National Provider Identifier (NPI) number is 1588726558.
What common questions do patients ask about Dr. Colevas?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Colevas
What is Dr. Alexander Colevas's specialty?
Dr. Colevas is a Medical Oncologist near Stanford, CA.
What does a Medical Oncologist do?
An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options.
Is this Dr. Alexander Colevas affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Colevas is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Medical Oncologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Medical Oncologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Alexander Colevas accepting new patients in Stanford, CA?
Yes, Dr. Alexander Colevas is accepting new patients at this time.
Does Dr. Alexander Colevas offer online booking?
Please contact Dr. Colevas's office at (650) 498-6000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Alexander Colevas?
Please contact Dr. Colevas's office at (650) 498-6000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Alexander Colevas have?
Dr. Alexander Colevas is certified by the American Board of Internal Medicine.
Other Medical Oncologist Near Stanford, CA
Medical Oncologist
Accepting patientsMedical Oncologist
Accepting patientsMedical Oncologist
Accepting patients